Acute Macular Degeneration and Sudden Vision Loss
Understanding Acute Macular Degeneration
Age-related macular degeneration affects the macula, the small central area of the retina responsible for sharp, detailed vision. AMD has two forms: dry and wet. Dry AMD is the more common form. It progresses gradually as the macula thins with age.
Wet AMD is less common but far more serious. It occurs when new, abnormal blood vessels grow underneath the retina. This process is called choroidal neovascularization. These fragile vessels can leak blood or fluid into the macula. The leaking damages the macula and can rapidly blur or destroy central vision.
The sudden onset of vision loss in wet AMD happens when the abnormal blood vessels rupture or leak. This causes fluid to build up under or within the retina. Bleeding may also occur in the macula. The result is rapid distortion or loss of central vision, sometimes within hours or days.
A signal protein called vascular endothelial growth factor, or VEGF, fuels the growth of these abnormal vessels. Without treatment, the leaking vessels can form a scar called a disciform scar. This scar replaces the normal structure of the outer retina and leads to severe, lasting central vision loss.
Dry AMD progresses slowly and may take years to affect vision significantly. Wet AMD can cause noticeable vision changes within days to weeks. Though wet AMD accounts for a smaller percentage of all AMD cases, it is responsible for approximately 90 percent of all AMD-related blindness (ASRS).
It is possible for dry AMD to convert to wet AMD at any time. This is why regular monitoring is essential for anyone diagnosed with any form of macular degeneration.
Who Is Affected and Risk Factors
AMD is one of the leading causes of vision loss in older adults. An estimated 19.83 million Americans were living with some form of AMD in 2019 (Prevent Blindness, 2022). Approximately 1.49 million had the late, vision-threatening form of the disease (Prevent Blindness, 2022). Among Medicare beneficiaries aged 65 and older in 2021, the national prevalence of AMD was 10.40 percent (PMC/VEHSS, 2021). Wet AMD specifically affected 2.14 percent of that population (PMC/VEHSS, 2021).
The primary risk factor for AMD is age. The older you are, the greater your risk becomes. People with a family history of AMD are also at higher risk. If a parent or sibling has been diagnosed with AMD, your own risk increases.
AMD is more common in people who are Caucasian or of European descent. Women are affected more often than men. Several lifestyle factors also contribute to risk:
- Smoking doubles the risk of AMD, and air pollution may also increase risk
- A diet high in saturated fats and low in antioxidants can raise the risk
- Uncontrolled cardiovascular disease or high blood pressure increases vulnerability
- Being overweight, particularly around the abdomen, is associated with higher risk
Signs and Symptoms
Wet AMD can produce dramatic changes in vision that develop quickly. The key warning signs include:
- A sudden loss of central vision in one eye
- Straight lines appearing bent, wavy, or distorted
- A dark or blurry area in the center of your vision
- Colors appearing less vivid or washed out
- Difficulty reading, recognizing faces, or seeing fine details
An Amsler grid is a simple tool that looks like graph paper with a dot in the center. You can use it at home to check for changes in your central vision. Testing takes less than a minute each day.
When using the grid, look for any change in how you see the lines. If lines appear wavy, broken, or missing, or if you notice a dark spot, contact a retina specialist promptly. Even subtle changes deserve attention.
Sudden changes in central vision should be treated as urgent. If you notice sudden dark spots, new blurriness, or straight lines that look bent or wavy, see a retina specialist or go to the emergency room immediately. Do not wait to see if symptoms improve on their own. Research suggests that treatment within the first 48 hours of symptom onset may lead to better visual outcomes (AMDF).
Diagnosis and Testing
A retina specialist will begin with a comprehensive dilated eye exam. Dilating drops widen the pupil so the specialist can examine the retina and macula in detail. This allows the specialist to look for signs of abnormal blood vessel growth, fluid, or bleeding beneath the retina.
Optical coherence tomography, or OCT, is a noninvasive imaging test that takes detailed cross-section pictures of the retina. It can reveal fluid buildup, swelling, or abnormal tissue beneath the macula. OCT is one of the most important tools for diagnosing and monitoring wet AMD. It detects changes that may not be visible during a standard exam.
In fluorescein angiography, a special dye is injected into a vein in the arm. As the dye travels through the blood vessels in the retina, a camera takes rapid photographs. This test shows where blood vessels are leaking. It helps the retina specialist determine the exact location and extent of the abnormal vessels.
OCT angiography, or OCTA, is a newer imaging technique that can map blood flow in the retina without injected dye. It provides detailed images of both normal and abnormal blood vessels. A retina specialist may use OCTA alongside other tests to get a complete picture of the condition.
Treatment Options
The primary treatment for wet AMD is anti-VEGF therapy. These are medications injected directly into the eye, known as intravitreal injections. Anti-VEGF drugs work by blocking vascular endothelial growth factor, the protein that drives abnormal blood vessel growth and leaking in the retina.
Before each injection, numbing eye drops are applied to minimize discomfort. While the idea of an eye injection may sound alarming, most patients report only brief, mild discomfort. Treatment can help stop further vision loss and, in many cases, may recover some lost vision.
Several anti-VEGF medications are available for treating wet AMD. The most commonly used options include:
- Eylea (aflibercept), typically given every four to eight weeks after an initial loading phase
- Lucentis (ranibizumab), typically given every four weeks
- Vabysmo (faricimab), a bispecific antibody that may allow dosing every four to sixteen weeks
- Avastin (bevacizumab), which is FDA-approved for cancer treatment but is widely used off-label for eye conditions, typically given every four to six weeks
Two newer treatment options may allow patients to receive fewer injections per year. Vabysmo (faricimab) and Eylea HD (high-dose aflibercept) have been shown to maintain treatment benefits with longer intervals between injections. Some patients may be able to extend visits to three or four times per year. A retina specialist will determine the appropriate schedule based on each patient's response to treatment.
Research indicates that the earlier anti-VEGF treatment begins after symptom onset, the better the visual outcome is likely to be. One recent study supported by the American Macular Degeneration Foundation suggests that time-to-treatment may be the single most important factor in preserving vision (AMDF). This is why any sudden change in central vision should prompt an immediate visit to a retina specialist.
What to Expect
Anti-VEGF treatment for wet AMD typically begins with a series of monthly injections called a loading phase. This usually involves three injections given four weeks apart. After the loading phase, the retina specialist will evaluate how the eye is responding using OCT imaging and other tests.
Based on the results, the specialist will create an ongoing treatment plan. Some patients may need injections every four to eight weeks. Others, particularly those on newer medications like Vabysmo or Eylea HD, may be able to extend the time between treatments.
Anti-VEGF therapy can stabilize vision and, in many cases, improve it. However, there is no current treatment that eliminates wet AMD entirely. The goal of treatment is to control the disease, reduce fluid and bleeding, and preserve as much vision as possible. Some patients experience significant visual improvement, while others maintain their current level of vision.
If a disciform scar has already formed before treatment begins, the central vision loss it caused is very likely to be lasting. This is another reason why prompt treatment is so important.
Wet AMD requires long-term monitoring even when treatment is working well. A retina specialist will schedule regular follow-up visits that include OCT scans and vision testing. These visits help detect any recurrence of fluid or bleeding early, before significant additional damage occurs.
Living With Acute Macular Degeneration
Lifestyle changes can support overall eye health and may help slow the progression of AMD. Quitting smoking is one of the most impactful steps, since smoking doubles the risk of AMD. Eating a diet rich in leafy green vegetables, fish, and other sources of antioxidants and omega-3 fatty acids may also be beneficial.
Maintaining a healthy weight, controlling blood pressure, and managing cardiovascular health are additional steps that support retinal health. Wearing sunglasses that block ultraviolet light can help protect the eyes from further damage.
Checking your vision with an Amsler grid each day is a simple but powerful habit. Cover one eye at a time and look at the grid in good lighting. If you notice any new distortion, waviness, or dark spots, contact your retina specialist right away. Early detection of recurrence or worsening can lead to earlier re-treatment and better outcomes.
For patients who have experienced significant central vision loss, low vision rehabilitation can help maximize the use of remaining eyesight. Low vision specialists can recommend magnifying devices, specialized lighting, large-print materials, and electronic aids. These tools can help people continue reading, cooking, and performing daily tasks more independently.
Sudden vision loss can be emotionally challenging. Feelings of frustration, anxiety, or sadness are common and understandable. Support groups for people with macular degeneration can provide practical advice and emotional encouragement. Organizations such as the American Macular Degeneration Foundation and the BrightFocus Foundation offer resources for patients and caregivers.
When to See a Retina Specialist
Certain symptoms require immediate medical attention. See a retina specialist or go to the emergency room right away if you experience:
- Sudden loss of central vision in one or both eyes
- A noticeable dark spot or blank area in the center of your vision
- Straight lines that suddenly appear wavy or distorted
- A rapid increase in visual distortion over hours or days
If you have been diagnosed with dry AMD, regular visits to a retina specialist are important. Dry AMD can convert to wet AMD at any time. Adults over age 50, especially those with a family history of AMD or other risk factors, should have a comprehensive dilated eye exam at least once a year. Your retina specialist will advise you on the appropriate monitoring schedule based on your individual risk.
Questions and Answers
There is no treatment that eliminates wet AMD entirely. However, anti-VEGF injection therapy can control the disease effectively in many patients. Treatment may stop further vision loss and, in some cases, improve vision. The key to the best possible outcome is starting treatment as soon as possible after symptoms begin.
Most patients with wet AMD require ongoing treatment for an extended period, often years. Some patients need injections throughout their lifetime to keep the disease under control. Over time, a retina specialist may be able to extend the interval between injections based on how well the eye responds. Newer medications like Vabysmo (faricimab) and Eylea HD (high-dose aflibercept) may allow longer intervals for some patients.
Yes. It is possible to have dry AMD in one eye and wet AMD in the other. It is also possible for both forms to exist in the same eye. If you have dry AMD, your retina specialist will monitor you closely for any signs of conversion to the wet form. Daily Amsler grid checks at home can help catch changes early between scheduled visits.
Dry AMD does not typically cause sudden vision loss. However, a form of advanced dry AMD called geographic atrophy can cause progressive vision decline. Two FDA-approved complement inhibitors are available for geographic atrophy. Syfovre (pegcetacoplan), a C3 inhibitor, and Izervay (avacincaptad pegol), a C5 inhibitor, can help slow the rate of geographic atrophy progression. These are intravitreal injections given monthly or every other month. They are specifically approved for geographic atrophy and are not used to treat wet AMD. If you experience sudden vision changes, the cause is more likely wet AMD or another condition. You should seek immediate evaluation from a retina specialist.
Without treatment, the abnormal blood vessels in wet AMD will continue to leak fluid and blood beneath the retina. Over time, this can lead to scarring of the macula, resulting in severe and lasting central vision loss. While peripheral vision is usually preserved, the loss of central vision can make it very difficult to read, drive, or recognize faces. Prompt treatment is essential to prevent irreversible damage.